289 High-level stabilized retinol serum balances bioactivity and dermal tolerance

Retinol, an established topical ingredient for improving signs of photo-aging, is often limited in concentration due to the potential low-level visible and sensory irritation. A new anhydrous, 0.5% stabilized retinol serum was developed, balancing bioactivity tolerability. This patented formula uses Relative Polarity Index (RPI) between skin, retinol, emollient ratios, allowing controlled bio-delivery skin. The product also includes skin-smoothing emollients, antioxidants stabilize retinol. Retinol tolerability were first evaluated through gene protein expression using human skin explants. Gene results indicated significant induction genes with anti-aging benefits, such as cellular retinoic-acid binding protein-2 (CRABP2), a highly sensitive marker retinoid bioactivity, Heparin-binding EGF-like growth factor (HBEGF), hyaluronan synthase-3 (HAS3). Additionally, minimal non-significant IL-8, inflammatory irritation marker, observed compared untreated controls. Histology demonstrated significantly increased collagen production. To further evaluate potential, clinical modified cumulative patch model developed differentiate products. found have less (p<0.05) versus competitive in-market formulation. 4-week in-use test performed assess facial tolerance self-perceived efficacy serum. Study concluded daily use well-tolerated, no statistically increases parameters. Moreover, self-perception questions yielded positive improvements on aging attributes, confirming our ex vivo results. delivers bioactive target advanced aging, without